PM
MYGN icon

Parametrica Management’s Myriad Genetics MYGN Stock Holding History

Parametrica Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,435
Closed -$204K – 305
2018
Q3 		$204K Buy
+4,435
New +$197K 0.45% 146
2017
Q2 		– Sell
-12,275
Closed -$236K – 340
2017
Q1 		$236K Buy
+12,275
New +$218K 0.25% 210

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parametrica Management's MYGN Position: Q4 2018 in Review

Parametrica Management sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 4,435 shares — an estimated $204K sold.

Parametrica Management first reported a position in MYGN in Q1 2017 and held it in 2 quarters. The position peaked at $236K in Q1 2017. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

  • Parametrica Management reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
  • Parametrica Management sold 4,435 Myriad Genetics shares in Q4 2018, an estimated $204K.
  • Parametrica Management first reported a position in Myriad Genetics in Q1 2017 and held it in 2 quarters.
  • Parametrica Management's Myriad Genetics position peaked at $236K in Q1 2017.
  • 264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Parametrica Management's 13F filing for Q4 2018, filed 12 Feb 2019.